Advancing digital health: FDA innovation during COVID-19
Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital he...
Main Authors: | Kushal Kadakia, Bakul Patel, Anand Shah |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-12-01
|
Series: | npj Digital Medicine |
Online Access: | https://doi.org/10.1038/s41746-020-00371-7 |
Similar Items
-
NODE.Health Meeting Report and Panel Discussion – The FDA’s Changing Regulatory Landscape for Digital Health Technologies and Digital Health Innovation during COVID-19: A Discussion with Eric Topol and Bakul Patel, Moderated by Aenor Sawyer
by: Anna Andoni, et al.
Published: (2020-12-01) -
FDA efficiency for approval process of COVID-19 therapeutics
by: Christine Cassidy, et al.
Published: (2020-12-01) -
Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period
by: Ramy H. Elshaboury, et al.
Published: (2021-09-01) -
Characteristics of pivotal trials and FDA review of innovative devices.
by: Joshua P Rising, et al.
Published: (2015-01-01) -
Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
by: Valentina L. Kouznetsova, et al.
Published: (2020-09-01)